Standard operating procedure: minnow takes the risk up to/including trials, toxicology, formulation etc, major company pays for the right to progress to market and sales. I'd imagine they will pay much more later on the development track ( less risk ) , rather than pay less at the early developmental stages (most risk).
Major pharmaceutical companies have their finger on every potential new/ongoing drug development ( & no they wouldn't be relying on HC threads for their market intelligence ).
Speculative M&A Transaction Analysis, page-729
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.000(0.00%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.35 | $254.2K | 185.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 212 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 5981 | 3 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |